Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer

NCT03410030 is registered in ClinicalTrials.gov with HonorHealth Research Institute as lead sponsor.

NCT NCT03410030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03410030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer
Lead sponsor
HonorHealth Research Institute
Phase
Phase 1/2
Overall status
Completed
Start date
December 15, 2017
Completion date
September 6, 2023
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas cancer, pancreas metastases, pancreatic adenocarcinoma resectable, pancreatic cancer, pancreatic ductal adenocarcinoma